小剂量美罗华联合地塞米松治疗难治性特发性血小板减少性紫癜11例被引量：3

下载PDF

导出

摘要目的探讨小剂量美罗华联合地塞米松治疗难治性特发性血小板减少性紫癜（ITP）的临床疗效.方法回顾性分析2009年10月至2011年6月我院收治的11例难治性ITP患者的临床诊治资料,均采用小剂量美罗华联合地塞米松治疗.结果 CR 6例,PR 2例,MR1例,NR2例,总有效率为81.8％（9/11）；半年以后随访,CR4例,PR3例,复发2例；3周内起效3例,3～6周起效4例,6周以上起效2例.结论小剂量美罗华联合地塞米松治疗难治性ITP有效率高,缓解时间短,继发感染的概率低,无明显毒副作用,并能减轻患者经济负担.

作者金阿荣

机构地区内蒙古自治区人民医院血液科

出处《海南医学》 CAS 2013年第20期3053-3054,共2页 Hainan Medical Journal

关键词难治性ITP 小剂量美罗华地塞米松

分类号 R554.6 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献6

1Psaila B,Busse JB.Refractory immune thrombo-cytopenic purpura:curret strategies for investigation and management [J].Br J Haema-tol,2008,143:16-26. 被引量：1
2Kojouri K,Vesely SK,Terrell DR,et al.Splenectomy for adult pa-tients with idiopathic ttirombocytopenic purpura:a systematic re-view to assess long term platelet count responses,prediction ofre-sponse,and surgical complications [J].Blood,2004,104:2623-2634. 被引量：1
3British Committee for Standards in Haematology General Haematol-ogy Task Force.Guidelines for the investigation and managementof idiopathic thrombocytopenic purpura in adults,children and inpregnancy [J].Br J Haematol,2003,120⑷:574-596. 被引量：1
4周泽平,杨仁池.B细胞清除治疗(美罗华)在ITP中的临床应用进展[J].国际输血及血液学杂志,2006,29(6):495-498. 被引量：9
5Stasi R,Pagano A,Stipa E,et al.Kituximab chimeric an-ti-CD20monoclonal antibody treatment for adults weith chron-ic id-iopathic thrombocytopenic purpura [J].Blood,2001,98:952-957. 被引量：1
6Provan D,ButierT,Evangelista ML,et al.Activity and safety profileof low-dose rituximab for the treatment of autoimmune cylopeniasin adults [J].Haematologica,2007,92(12):1695-1698. 被引量：1

二级参考文献20

1Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr,2005,146(2):217 221. 被引量：1
2Bennett CM,Rogers ZR,Kinnamon DD,et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006, 107(7): 2639-2642. 被引量：1
3Penalver FJ ,Jimenez-Yuste V, Almagro M ,et al. On behalf of the Multi-institutional Retrospective Spanish Study on the use of rituximab in refractory ITP. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol, 200685 (6) : 400-406. 被引量：1
4Cesaro S,Bisogno G,Pusiol A. Rituximab and factors predictive of response in chronic immune thrombocytopenic purpura of children. J Pediatr,2005,147(5):715-716. 被引量：1
5British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults,children and in pregnancy. Br J Haematol, 2003, 120(4) :574-596. 被引量：1
6McFarland J. Pathophysiology of platelet destruction in immune(idiopathic) thrombocytopenic purpura. Blood Rev, 2002,16 ( 1 ) : 1-2. 被引量：1
7Anolik J,Sanz I,Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep,2003,5(5) :350-356. 被引量：1
8Hultin LE,Hausner MA,Hultin PM,et al. CD20 (pan-B cell)antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry,1993,14: 196-204. 被引量：1
9Reff ME,Carner K,Chambers KS,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood,1994,83(2) :435-444. 被引量：1
10Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol, 2004,83 ( 10 ) : 634-645. 被引量：1